JPWO2018073393A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2018073393A5
JPWO2018073393A5 JP2019520685A JP2019520685A JPWO2018073393A5 JP WO2018073393 A5 JPWO2018073393 A5 JP WO2018073393A5 JP 2019520685 A JP2019520685 A JP 2019520685A JP 2019520685 A JP2019520685 A JP 2019520685A JP WO2018073393 A5 JPWO2018073393 A5 JP WO2018073393A5
Authority
JP
Japan
Prior art keywords
receptor
antigen
protein
molecule
family
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019520685A
Other languages
English (en)
Japanese (ja)
Other versions
JP7236380B2 (ja
JP2019531742A (ja
JP2019531742A5 (enExample
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/076800 external-priority patent/WO2018073393A2/en
Publication of JP2019531742A publication Critical patent/JP2019531742A/ja
Publication of JP2019531742A5 publication Critical patent/JP2019531742A5/ja
Publication of JPWO2018073393A5 publication Critical patent/JPWO2018073393A5/ja
Application granted granted Critical
Publication of JP7236380B2 publication Critical patent/JP7236380B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019520685A 2016-10-19 2017-10-19 治療に適したtalエフェクターヌクレアーゼ(talen)改変同種異系細胞 Active JP7236380B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662410187P 2016-10-19 2016-10-19
US62/410,187 2016-10-19
DKPA201770240 2017-03-31
DKPA201770240 2017-03-31
PCT/EP2017/076800 WO2018073393A2 (en) 2016-10-19 2017-10-19 Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy

Publications (4)

Publication Number Publication Date
JP2019531742A JP2019531742A (ja) 2019-11-07
JP2019531742A5 JP2019531742A5 (enExample) 2020-11-19
JPWO2018073393A5 true JPWO2018073393A5 (enExample) 2023-01-25
JP7236380B2 JP7236380B2 (ja) 2023-03-09

Family

ID=60268352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019520685A Active JP7236380B2 (ja) 2016-10-19 2017-10-19 治療に適したtalエフェクターヌクレアーゼ(talen)改変同種異系細胞

Country Status (5)

Country Link
US (1) US20230138915A1 (enExample)
EP (1) EP3529265A2 (enExample)
JP (1) JP7236380B2 (enExample)
AU (1) AU2017347685B2 (enExample)
CA (1) CA3041039A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021008082A2 (pt) 2018-11-07 2021-08-10 Crispr Therapeutics Ag terapia contra o câncer com células imunitárias anti-liv1
CA3185455A1 (en) * 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
CN117129690B (zh) * 2023-09-26 2025-06-06 杭州师范大学 Grhl1在her2-乳腺癌诊断及预后评估中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111676196A (zh) * 2012-05-25 2020-09-18 塞勒克提斯公司 工程化异体和免疫抑制耐受性t细胞的方法
EP3309248B1 (en) * 2013-05-29 2021-06-09 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
KR102228828B1 (ko) * 2014-03-11 2021-03-16 셀렉티스 동종이형 이식에 양립성인 t-세포들을 만들어내는 방법
WO2016124765A1 (en) * 2015-02-06 2016-08-11 Cellectis Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
BR112017020750A2 (pt) * 2015-03-27 2018-06-26 Harvard College células t modificadas e métodos de produção e utilização das mesmas
JP6816133B2 (ja) * 2015-10-05 2021-01-20 プレシジョン バイオサイエンシズ,インク. 改変ヒトt細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞
CA3019199A1 (en) * 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof

Similar Documents

Publication Publication Date Title
IL273201B1 (en) Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy
JP2025037871A5 (enExample)
JPWO2021188599A5 (enExample)
Lin et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
IL273948B1 (en) Compositions and methods for selective protein degradation
RU2018122106A (ru) Буферы для стабилизации лентивирусных препаратов
JP2020517263A5 (enExample)
IL297547A (en) Therapeutic interventional particles for the corona virus
US12305186B2 (en) Methods for expanding SARS-COV2-antigen-specific t cells, compositions and uses related thereto
IL297514A (en) Vectors and methods for in vivo transduction
HRP20230457T1 (hr) Pripravci i postupci za selektivnu ekspresiju kimernih antigenskih receptora
US20210095029A1 (en) Compositions and methods for treating cancer
JPWO2020033927A5 (enExample)
KR20210126008A (ko) 세포 면역 치료의 조합
CN110511912B (zh) 免疫细胞的功能调节
CA3164666A1 (en) Bcma-directed cellular immunotherapy compositions and methods
JPWO2022178367A5 (enExample)
WO2021057906A1 (zh) 表达il-15的免疫效应细胞
EP4232566A1 (en) Chimeric activation receptors
JPWO2018073393A5 (enExample)
JPWO2021041806A5 (enExample)
JP2019531742A5 (enExample)
US11701385B2 (en) Modulation of cell function for immunotherapy
JPWO2022241036A5 (enExample)
JPWO2021231505A5 (enExample)